Dianthus Therapeutics Inc (NASDAQ: DNTH) on Monday, soared 5.38% from the previous trading day, before settling in for the closing price of $41.45. Within the past 52 weeks, DNTH’s price has moved between $13.36 and $43.67.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 40.14%. The company achieved an average annual earnings per share of -45.75%. With a float of $32.54 million, this company’s outstanding shares have now reached $42.85 million.
Dianthus Therapeutics Inc (DNTH) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Dianthus Therapeutics Inc is 24.12%, while institutional ownership is 95.27%. The most recent insider transaction that took place on Nov 14 ’25, was worth 4,158,442. In this transaction EVP, Head of R&D of this company sold 109,031 shares at a rate of $38.14, taking the stock ownership to the 4,000 shares. Before that another transaction happened on Nov 13 ’25, when Company’s EVP, Head of R&D sold 87,507 for $36.81, making the entire transaction worth $3,221,445. This insider now owns 4,000 shares in total.
Dianthus Therapeutics Inc (DNTH) Performance Highlights and Predictions
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.7 earnings per share (EPS) for the period topping the consensus outlook (set at -0.76) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -45.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -17.45% during the next five years compared to 40.14% growth over the previous five years of trading.
Dianthus Therapeutics Inc (NASDAQ: DNTH) Trading Performance Indicators
Dianthus Therapeutics Inc (DNTH) is currently performing well based on its current performance indicators. A quick ratio of 17.35 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 608.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.49, a number that is poised to hit -1.07 in the next quarter and is forecasted to reach -3.65 in one year’s time.
Technical Analysis of Dianthus Therapeutics Inc (DNTH)
The latest stats from [Dianthus Therapeutics Inc, DNTH] show that its last 5-days average volume of 1.03 million was superior to 0.46 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 78.67%.
During the past 100 days, Dianthus Therapeutics Inc’s (DNTH) raw stochastic average was set at 97.99%, which indicates a significant increase from 95.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.64 in the past 14 days, which was higher than the 1.97 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $36.57, while its 200-day Moving Average is $24.85. Now, the first resistance to watch is $44.59. This is followed by the second major resistance level at $45.51. The third major resistance level sits at $46.80. If the price goes on to break the first support level at $42.38, it is likely to go to the next support level at $41.09. Assuming the price breaks the second support level, the third support level stands at $40.17.
Dianthus Therapeutics Inc (NASDAQ: DNTH) Key Stats
Market capitalization of the company is 1.87 billion based on 42,876K outstanding shares. Right now, sales total 6,240 K and income totals -84,970 K. The company made 400 K in profit during its latest quarter, and -36,770 K in sales during its previous quarter.
